目的 本实验旨在探讨人参总皂苷与化疗药物依托泊苷联合使用时是否存在药动学上的相互作用,为临床合理用药提供参考。方法 将18只雄性Wistar大鼠随机分为3组,分别为依托泊苷对照组(10 mgkg-1)、人参皂苷高剂量组(依托泊苷10 mgkg-1+人参总皂苷200 mgkg-1)、人参皂苷低剂量组(依托泊苷10 mgkg-1+人参总皂苷100 mgkg-1)。于给药前及给药后不同时间点由大鼠眼眶静脉丛采血,用高效液相色谱法(HPLC)检测依托泊苷的血药浓度,用DAS3.2.7 软件计算药动学参数。结果 高剂量人参总皂苷联合用药组与对照组相比,AUC0-t上升了46%,MRT0-t增加了24%,CL下降了19%,统计学上有显著性差异。低剂量联合用药组与对照组相比,AUC0-t上升了21%,P<0.05,统计学上有显著性差异。其他药动学参数统计学上无显著性差异。结论 人参总皂苷与依托泊苷联合用药时,可提高依托泊苷的血药浓度,降低其血浆清除率,这种影响程度与剂量相关。
Abstract
OBJECTIVE To investigate the pharmacokinetic interaction between ginsenosides and etoposide and provide useful information for clinical practice. METHODS Eighteen male Wistar rats were randomly divided into three groups: etoposide group(10 mgkg-1),the high dose ginsenoside group(etoposide 10 mgkg-1, ginsenoside 200 mgkg-1), the low dose ginsenoside group(etoposide 10 mgkg-1, ginsenoside 100 mgkg-1). Plasma samples were collected at different times after the drug administration from the orbital veins of the rats. An HPLC method was developed to determine the concentration of etoposide in rat plasma,and the pharmacokinetic parameters were calculated using DAS3.2.7. RESULTS Compared with the etoposide group,AUC0-t and MRT0-t of the high dose ginsenoside group were increased by 46% and 24% respectively, and CL decreased by 19%, which was statistically significant difference. The AUC0-t of the low dose ginsenoside group had a significant increased(21%) compared with the etoposide group, while other pharmacokinetic parameters had no significant differences. CONCLUSION Combination of ginsenosides and etoposide could significantly improve the plasma concentration and reduce excretion of etoposide.
关键词
人参总皂苷 /
依托泊苷 /
药动学 /
药物相互作用
{{custom_keyword}} /
Key words
ginsenoside /
etoposide /
pharmacokinetics /
drug interaction
{{custom_keyword}} /
中图分类号：
R969.1
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] FAN L, XIE H T, ZHOU H H. Herb-drug interactions in oncology and potential mechanisms. Chin J Clin Pharmacol Ther(中国临床药理学与治疗学杂志), 2007,12(2):134-139.
[2] MATHIJSSEN R H, VERWEIJ J, DE B P, et al. Effects of St. John′s wort on irinotecan metabolism. J Natl Cancer Inst, 2002, 94(16):1247-1252.
[3] CHIANG H M, FANG S H, WEN K C, et al. Life-threatening interaction between the root extract of Pueraria lobata and methotrexate in rats. Toxicol Appl Pharmacol, 2005, 209(3):263-268.
[4] REIF S, NICOLSON M C, BISSET D, et al. Effect of grapefruit juice intake on etoposide bioavailability. Eur J Clin Pharmacol, 2002, 58(7):491-494.
[5] HARKEY M R, HENDERSON G L, GERSHWIN M E, et al. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr, 2001, 73(6):1101-1106.
[6] ZHOU J C.Practice of Medical Oncology(实用肿瘤内科学). Vol 2.Beijing:People′s Medical Publishing House,2010: 286-287.
[7] REN L L,WEI Y F,DU H L. Advance of research on antitumour activity of Ginseng. Chin Tradit Pat Med(中成药),2005,27(8):947-950.
[8] TANG B,CHENG X J,LIU J, et al. Advance of research on pharmacological action of Ginsenoside. J Milit Surge Southwest China J(西南军医),2005,7(3):45-47.
[9] YANG Y L,DU Q,DUN J N. Properties and pharmacokinetic studies on etoposide-loaded chitosan microspheres for nasal administration.Chin Pharm J(中国药学杂志),2008,43(4):284-287.
[10] TIAN L L, TANG X, HE H B, et al. Preparation and in vitro and in vivo evaluation of etoposide submicro-emulsion for intravenous injection. Acta Pharm Sin(药学学报), 2007, 42(8):892-897.
[11] FANG S H, LI B Q, YANG G Q, et al. Preclinical pharmacokinetics and tissue distribution of nanoparticle of etoposide for injection. J Shenyang Pharm Univ(沈阳药科大学学报), 2010, 27(10):840-843.
[12] YAO T W.Biopharmaceutic Analysis(体内药物分析). Hangzhou:Zhejiang University Press,2012:26.
[13] CAO Y L, DU X L, ZHU Z, et al. HPLC Assay for determination of etoposide in human plasma. Chin Pharm J(中国药学杂志), 2011, 46(11):857-859.
[14] YUAN H Y, LI H D. Research progress of herb-chemotherapeutics interactions. Chin J New Drugs(中国新药杂志), 2007, 16(18):1450-1453.
[15] LIU Z J,FU D X,SUN C H,et al. Advances of in vivo drug interaction studies. Adv Drug React J(药物不良反应杂志), 2006, 8(1):33-38.
[16] LUU A, FOSTER B C, MCINTYRE K L, et al. Pharmacogenetics in Potential Herb-Drug Interactions: Effects of Ginseng on CYP3A4 and CYP2C9 Allelic Variants. New York:Springer, 2011:59-65.
[17] LIU Y.Application of Early Drug Metabolism in Scientific Evaluation of Traditional Chinese Medicine-Drug-Drug Interactions by Intestinal Bacteria Metabolites of Naturally Occurring Ginsenosides. Dalian:Dalian Institute of Chemical Physics,2006.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(1258 KB)
